Research programme: abuse-deterrent oral hydrocodone controlled-release - Egalet/Shionogi

Drug Profile

Research programme: abuse-deterrent oral hydrocodone controlled-release - Egalet/Shionogi

Alternative Names: AD Combination hydrocodone; AD ER hydrocodone; Hydrocodone controlled release - Egalet/Shionogi

Latest Information Update: 20 Nov 2015

Price : $50

At a glance

  • Originator Egalet
  • Class Antitussives; Morphinans; Opioid analgesics; Opioid peptides; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Pain

Most Recent Events

  • 12 Nov 2015 Egalet has patent protection for Guardian™ Technology in USA
  • 01 Jun 2015 Abuse-deterrent product candidates containing hydrocodone is still in preclinical development for Pain in Japan (Egalet 10-Q, June 2015)
  • 26 Nov 2013 Preclinical trials in Pain in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top